CN100518775C - Medicine composition for treating cough and asthma and preparation thereof - Google Patents
Medicine composition for treating cough and asthma and preparation thereof Download PDFInfo
- Publication number
- CN100518775C CN100518775C CNB2007100175557A CN200710017555A CN100518775C CN 100518775 C CN100518775 C CN 100518775C CN B2007100175557 A CNB2007100175557 A CN B2007100175557A CN 200710017555 A CN200710017555 A CN 200710017555A CN 100518775 C CN100518775 C CN 100518775C
- Authority
- CN
- China
- Prior art keywords
- parts
- cough
- asthma
- pharmaceutical composition
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 208000006673 asthma Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 16
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 8
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 8
- 229960004559 theobromine Drugs 0.000 claims abstract description 8
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 14
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 10
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 7
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 7
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 7
- 229960003529 diazepam Drugs 0.000 claims description 7
- 229960002800 prednisolone acetate Drugs 0.000 claims description 7
- 229960000278 theophylline Drugs 0.000 claims description 7
- XOWALWSEFODFBC-UHFFFAOYSA-N C1=CC=NC=C1.COC1=CC=CC=C1 Chemical compound C1=CC=NC=C1.COC1=CC=CC=C1 XOWALWSEFODFBC-UHFFFAOYSA-N 0.000 claims description 6
- KWGRBVOPPLSCSI-WPRPVWTQSA-N L-Ephedrine Natural products CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 6
- 229960002179 ephedrine Drugs 0.000 claims description 6
- -1 ephedrine hydrochlorides Chemical class 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 229940025250 camphora Drugs 0.000 claims description 4
- 239000010238 camphora Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 abstract description 2
- 229960003563 calcium carbonate Drugs 0.000 abstract description 2
- 229960002534 ephedrine hydrochloride Drugs 0.000 abstract description 2
- 229960003885 sodium benzoate Drugs 0.000 abstract description 2
- 229960005404 sulfamethoxazole Drugs 0.000 abstract description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 abstract description 2
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 239000001848 glycyrrhiza glabra l. root extract powder Substances 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 239000010676 star anise oil Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 201000006306 Cor pulmonale Diseases 0.000 description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000009612 Laryngismus Diseases 0.000 description 2
- 206010023891 Laryngospasm Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical compound O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a medicine composition for curing cough and asthma. It is made up by using bitter apricot, crude gypsum, licorice extract powder, star anise oil, camphor, ephedrine hydrochloride, calcium carbonate, sodium benzoate, sulfamethoxazole, methoxybentine and theobromine through a certain preparation process. Said medicine has good therapeutic effect for curing cough, asthma and infection of respiratory tract.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of pharmaceutical composition for the treatment of cough with asthma; The present invention relates to the oral formulations of this pharmaceutical composition simultaneously.
Background technology
According to incompletely statistics, the human patient who suffers from various coughs accounts for about 30% of population, and the patient of postinfectious cough is countless especially.Asthma patient is because the spasm at hypersensitive larynx bronchus position more than 80%, and dyspnea causes vital capacity to reduce then, and the blood anoxia is so that whole body severe depletion of oxygen makes patient mouth bluish lip purple, in the larynx alluvial expectorant toot etc.Because the human body anoxia, each internal organs dysfunction of the spleen in transportation and transformation makes too much moisture content can not in time excrete phlegm caused by accumulation of body fluid, and the difficult expectoration of abundant expectoration.The medicine of treatment cough at present, asthma is a lot, but satisfactory for result and few.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition that can effectively treat cough, asthma, this medicine adopts the bonded mode of Chinese medicine and western medicine, the lasting medicine of Chinese medicine, the characteristics of Western medicine instant effect have been utilized, through rational formula, respectively get the chief, make it play the effect of relieving cough and resolving phlegm, releasing laryngospasm in a short period of time.
Another object of the present invention provides the oral formulations of this pharmaceutical composition.
The present invention treats the pharmaceutical composition of cough with asthma, crude drug by following weight ratio part is prepared from: 5～15 parts of Semen Armeniacae Amarums, 15～25 parts of Gypsum Fibrosum, 15～25 parts of Radix Glycyrrhizae extractum powders, 5～10 parts of Oleum Anisi Stellati, 1～5 part of Camphora, 5～10 parts of ephedrine hydrochlorides, 10～20 parts of calcium carbonate, 5～15 parts of sodium benzoate, 3～10 parts of sulfamethoxazoles, 1～6 part of methoxy benzene pyridine, 0.1～0.5 part of diazepam, 5～15 parts of theophylline, 5～10 parts of theobromine, 5～15 parts in Semen daturae extractum powder, 0.1～0.5 part of prednisolone acetate.
Pharmaceutical composition of the present invention can adopt the common process and the adjuvant of pharmaceutics, is prepared into any oral formulations on the pharmaceutics.
Pharmaceutical composition of the present invention is the bonded product of Chinese and western drugs, and Chinese medicinal components Semen Armeniacae Amarum wherein, Gypsum Fibrosum, Radix Glycyrrhizae extractum, Oleum Anisi Stellati, Camphora have that lung qi dispersing is regulated the flow of vital energy, the effect of preventing phlegm from forming and stopping coughing, releasing laryngospasm, antiallergic; Western medicine component ephedrine hydrochloride, calcium carbonate, sodium benzoate, sulfamethoxazole, the pyridine of methoxy benzene, diazepam, theophylline, theobromine, Semen daturae extractum powder, prednisolone acetate have the effect of relieving cough and resolving phlegm, the two combines, and cough, abundant expectoration cough, the no productive cough that chronic cough after bronchial asthma cough, pulmonary heart disease cough, pulmonary carcinoma cough, pulmonary tuberculosis cough, the flu is not healed multiple cough such as cough all has good therapeutical effect.
Illustrate that below by anxious toxicity test of animal and clinical trial pharmaceutical composition of the present invention is in sick effect such as the various coughs of treatment, asthma and to the side effect of human body.
One, animal acute toxicity experiment
1, test objective: observe medicine of the present invention and once give the acute toxic reaction and the death condition that are produced behind the mice.
2, experimental animal: Kunming kind hybridize mice, 20, male and female half and half, body weight 18.7-20.6 (19.7 ± 0.6) g.Feed pellet, the drink ordinary water.
3, trial drug: with the drug rehabilitation extractum that prescription of the present invention extracts, every milliliter of suitable 2.96g crude drug of extractum.Receive in 1% carbonyl formaldehyde cellulose during use and be made into 1.48g.ml concentration (crude drug).
4, medication: the animal fasting is after 4 hours, once press 0.4ml/10g body weight (liquor strength 1.48g/ml), containing crude drug is 0.4 * 1.48=0.592 (g/10g body weight), and then an ig dosage is 59.29/kg, 247 times of quite clinical recommendation consumption 0.24g/kg.
5, observation index: observe the animal hair color after the administration day by day, behavioral activity, the mental status, a big young waiter in a wineshop or an inn just, nose, eye, mouthful secretions, body weight change (1-7 natural gift another name weight after the medication).Death state, if find that death in time performs an autopsy on sb, the pathological changes organ pipe is done the pathology histological examination.
6 results:
6.1 do not see epilation, movable mental status, two just obviously change; Nose, eye, courageous and upright and other secretions of mouthful nothing, none example is dead.
6.2 two sex mice body weight through the time change and to see the following form 1,2.
Table 1 is irritated the influence of stomach to female Mus body weight
Table 2 is irritated the influence of stomach to male Mus body weight
7, conclusion
Average weight increases day by day to after giving the medicine of prescription of the present invention 7.1 two sex mices are disposable, and none example is dead.
7.2 disposable give of mice gives medicine of the present invention, its maximum tolerated dose〉39.29/kg (crude drug) 189 times of quite clinical recommendation consumption approximately.
Two, clinical trial
1, case is selected:
1.1 cough behind the children's cold: infant was 56 person-times in 1-2 years old, and infant was 32 person-times in 3-4 years old, and infant was 70 person-times in 4-6 years old, and infant was 82 person-times in 8-12 years old, totally 240 person-times.
1.2 adult patients: asthmatic patient 57 people more than 40 years old, asthmatic patient 19 people more than 30 years old, 32 people of asthmatic patient below 30 years old, totally 108 people; Patient 678 people of flu future trouble cough.
2, Therapeutic Method: the capsule preparations of taking pharmaceutical composition of the present invention.Dose: 1-2 years old infants: 0.04～0.06g; 3-4 years old infants: 0.04～0.06g; 4-6 years old infants: 0.06～0.08g; 8-12 years old infants: 0.1～0.2; Adult: 0.6～0.8g; 10 days is a course of treatment, coughs behind the children's cold: generally be 0.5 course of treatment, the adult patients postinfectious cough general 1～5 day was a course of treatment; Senile asthma and cough generally is 5～6 courses of treatment.
4, therapeutic outcome:
Please add up various case patients' treatment situation respectively:
Infant 55 examples were cured fully in 1-2 years old, and 1 example cough alleviates, and 0 example is invalid.The statistics effective percentage is 98%;
3-4 years old infants: 32 examples are cured fully, and 0 example is invalid.The statistics effective percentage is 100%;
4-6 years old infants: 70 examples are cured fully, and 0 example is invalid.The statistics effective percentage is 100%;
8-12 years old infants: 82 examples are cured fully, and 0 example is invalid.。The statistics effective percentage is 100%;
Adult's asthma: 100 examples are cured fully, and 8 example coughs alleviate, and 0 example is invalid.The statistics effective percentage is 92.5%;
Adult's postinfectious cough: 678 examples are cured fully, and 0 example is invalid.The statistics effective percentage is 100%.
Vertical the above, the medicine of the present invention prior art that heals is compared and is had the following advantages:
1, medicine of the present invention to bronchial asthma cough, pulmonary heart disease cough, pulmonary carcinoma cough, pulmonary tuberculosis cough, flu after the multiple cough such as cough of the chronic cough cough, abundant expectoration cough, the no productive cough that do not heal good therapeutical effect is all arranged.
2, medicine of the present invention has curative effect fast (generally take can take effect in back 5 minutes), and consumption is little, and (asthmatic patient every day of tussiculaing is oral twice, each 0.6～0.8g; Asthmatic patient every day that patients with cor pulmonale, persistent ailment are not changed is oral twice, each 0.6～0.8g; Extra heavy patient every day is oral twice, and each 0.8～1g is a maximum dose; Flu causes patient every day oral twice, each 0.6～0.8g) of cough.
3, medicine of the present invention has no side effect, safety, reliable, harmless.
The specific embodiment
The preparation of embodiment 1, capsule of the present invention:
Prescription: in weight ratio part: 5 parts of Semen Armeniacae Amarums, 15 parts of Gypsum Fibrosum, 15 parts of Radix Glycyrrhizae extractum powders, 5 parts of Oleum Anisi Stellati, 1 part of Camphora, 10 parts of ephedrine hydrochlorides, 20 parts of calcium carbonate, 15 parts of sodium benzoate, 10 parts of sulfamethoxazoles, 4 parts of methoxy benzene pyridines, 0.3 part of diazepam, 10 parts of theophylline, 8 parts of theobromine, 10 parts in Semen daturae extractum powder, 0.3 part of prednisolone acetate.
Technology: adopt the conventional adjuvant and the technology of preparation capsule, be prepared into capsule.
The preparation of embodiment 2, pill of the present invention
Prescription: in weight ratio part:
10 parts of Semen Armeniacae Amarums, 20 parts of Gypsum Fibrosum, 20 parts of Radix Glycyrrhizae extractum powders, 7 parts of Oleum Anisi Stellati, 3 parts of Camphoras, 5 parts of ephedrine hydrochlorides, 10 parts of calcium carbonate, 5 parts of sodium benzoate, 3 parts of sulfamethoxazoles, 6 parts of methoxy benzene pyridines, 0.5 part of diazepam, 15 parts of theophylline, 10 parts of theobromine, 15 parts in Semen daturae extractum powder, 0.5 part of prednisolone acetate.
Technology: adopt the conventional adjuvant and the technology of preparation pill, be prepared into pill.
The preparation of embodiment 3, medicine granule of the present invention
Prescription: in weight ratio part:
15 parts of Semen Armeniacae Amarums, 25 parts of Gypsum Fibrosum, 25 parts of Radix Glycyrrhizae extractum powders, 10 parts of Oleum Anisi Stellati, 5 parts of Camphoras, 7 parts of ephedrine hydrochlorides, 15 parts of calcium carbonate, 10 parts of sodium benzoate, 5 parts of sulfamethoxazoles, 4 parts of methoxy benzene pyridines, 0.1 part of diazepam, 5 parts of theophylline, 5 parts of theobromine, 5 parts in Semen daturae extractum powder, 0.5 part of prednisolone acetate.
Technology: adopt the conventional adjuvant and the technology of preparation granule, be prepared into granule.
The preparation of embodiment 4, tablet of the present invention:
Prescription: in weight ratio part:
10 parts of Semen Armeniacae Amarums, 20 parts of Gypsum Fibrosum, 20 parts of Radix Glycyrrhizae extractum powders, 7 parts of Oleum Anisi Stellati, 3 parts of Camphoras, 8 parts of ephedrine hydrochlorides, 15 parts of calcium carbonate, 10 parts of sodium benzoate, 7 parts of sulfamethoxazoles, 4 parts of methoxy benzene pyridines, 0.3 part of diazepam, 10 parts of theophylline, 8 parts of theobromine, 10 parts in Semen daturae extractum powder, 0.3 part of prednisolone acetate.
Technology: adopt the conventional adjuvant and the technology of preparation tablet, be prepared into tablet.
Claims (6)
1, a kind of pharmaceutical composition for the treatment of cough with asthma, crude drug by following weight ratio part is prepared from: 5～15 parts of Semen Armeniacae Amarums, 15～25 parts of Gypsum Fibrosum, 15～25 parts of Radix Glycyrrhizae extractum powders, 5～10 parts of Oleum Anisi Stellati, 1～5 part of Camphora, 5～10 parts of ephedrine hydrochlorides, 10～20 parts of calcium carbonate, 5～15 parts of sodium benzoate, 3～10 parts of sulfamethoxazoles, 1～6 part of methoxy benzene pyridine, 0.1～0.5 part of diazepam, 5～15 parts of theophylline, 5～10 parts of theobromine, 5～15 parts in Semen daturae extractum powder, 0.1～0.5 part of prednisolone acetate.
2, treat the pharmaceutical composition of cough with asthma according to claim 1, it is characterized in that: adopt the common process and the adjuvant of pharmaceutics, be prepared into any oral formulations on the pharmaceutics.
3, as the pharmaceutical composition of treatment cough with asthma as described in the claim 2, it is characterized in that: adopt the conventional adjuvant and the technology of preparation tablet, be prepared into tablet.
4, as the pharmaceutical composition of treatment cough with asthma as described in the claim 2, it is characterized in that: adopt the conventional adjuvant and the technology of preparation capsule, be prepared into capsule.
5, as the pharmaceutical composition of treatment cough with asthma as described in the claim 2, it is characterized in that: adopt the conventional adjuvant and the technology of preparation pill, be prepared into pill.
6, as the pharmaceutical composition of treatment cough with asthma as described in the claim 2, it is characterized in that: adopt the conventional adjuvant and the technology of preparation granule, be prepared into granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100175557A CN100518775C (en) | 2007-03-16 | 2007-03-16 | Medicine composition for treating cough and asthma and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100175557A CN100518775C (en) | 2007-03-16 | 2007-03-16 | Medicine composition for treating cough and asthma and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101024014A CN101024014A (en) | 2007-08-29 |
| CN100518775C true CN100518775C (en) | 2009-07-29 |
Family
ID=38742856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100175557A Expired - Fee Related CN100518775C (en) | 2007-03-16 | 2007-03-16 | Medicine composition for treating cough and asthma and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100518775C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009048326A2 (en) * | 2007-10-10 | 2009-04-16 | Snp Bioscience B.V. | Preparation for treatment of a pulmonary disease |
| GB0921805D0 (en) * | 2009-12-14 | 2010-01-27 | Biocopea Ltd | Drug composition and its use in therapy |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
-
2007
- 2007-03-16 CN CNB2007100175557A patent/CN100518775C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101024014A (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101797347B (en) | Traditional Chinese medicinal composition for treating gastrointestinal tract and preparation thereof | |
| CN100518775C (en) | Medicine composition for treating cough and asthma and preparation thereof | |
| CN105412858A (en) | Syrup and preparation method thereof | |
| CN101766787B (en) | Enema liquid for treating hyperpyrexia and cough and asthma | |
| CN101322761A (en) | Medicament for treating tracheitis and bronchitic and preparation thereof | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| WO2021093090A1 (en) | Traditional chinese medicine extract composition having function of regulating depression, preparation method therefor, and chinese medicine preparation | |
| CN103816281B (en) | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold | |
| CN1175885C (en) | Zibei Cough stopping granules and its preparation method | |
| CN101129755A (en) | Orally taken traditional Chinese medicine composition for treating asthma | |
| CN101708207B (en) | Medicinal composition for expelling phlegm and inhibiting cough and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN102526236A (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN104257803A (en) | Pharmaceutical composition for treating snore as well as preparation method and application of pharmaceutical composition | |
| CN101549051B (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN1193777C (en) | Chinese medicine for curing cold by omphalotherapy and its preparing process | |
| CN104189076B (en) | A kind of Traditional Chinese medicine plaster for treating children's cold asthma and preparation method thereof | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN101537147B (en) | Anaesthetic prescription for treating pulmonary tuberculosis and preparation method thereof | |
| CN102204956A (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN106215080A (en) | A kind of pharmaceutical composition for the treatment of bronchial asthma of child containing Procaterol Hydrochloride and preparation method thereof | |
| CN102178757B (en) | Medicinal composition containing ferment caterpillar fungus powder and pears serving as raw materials | |
| CN111228455A (en) | A Chinese medicinal preparation for treating cough and asthma | |
| CN107854546A (en) | Dog, cat cough suppressing medicine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090729 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |